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Abstract
Retinitis Pigmentosa (RP) is a common form of retinal degeneration characterized by photoreceptor degeneration and
retinal pigment epithelium (RPE) atrophy causing loss of visual field and acuities. Exome sequencing identified a novel
homozygous splice site variant (c.111+1G.A) in the gene encoding retinol binding protein 4 (RBP4). This change
segregated with early onset, progressive, and severe autosomal recessive retinitis pigmentosa (arRP) in an eight member
consanguineous pedigree of European ancestry. Additionally, one patient exhibited developmental abnormalities including
patent ductus arteriosus and chorioretinal and iris colobomas. The second patient developed acne from young age and
extending into the 5th decade. Both patients had undetectable levels of RBP4 in the serum suggesting that this mutation led
to either mRNA or protein instability resulting in a null phenotype. In addition, the patients exhibited severe vitamin A
deficiency, and diminished serum retinol levels. Circulating transthyretin levels were normal. This study identifies the RBP4
splice site change as the cause of RP in this pedigree. The presence of developmental abnormalities and severe acne in
patients with retinal degeneration may indicate the involvement of genes that regulate vitamin A absorption, transport and
metabolism.
Citation: Cukras C, Gaasterland T, Lee P, Gudiseva HV, Chavali VRM, et al. (2012) Exome Analysis Identified a Novel Mutation in the RBP4 Gene in a
Consanguineous Pedigree with Retinal Dystrophy and Developmental Abnormalities. PLoS ONE 7(11): e50205. doi:10.1371/journal.pone.0050205
Editor: Andreas R. Janecke, Innsbruck Medical University, Austria
Received July 26, 2012; Accepted October 17, 2012; Published November 26, 2012
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: This work was supported by grants from the Department of Biotechnology:Indo-US Vision Research Program, Department of Science & Technology,
Government of India, Foundation Fighting Blindness USA, Research to Prevent Blindness, the NIH Intramural Research Program, National Institutes of Health
grants EY013198, EY021237, EY022306 and EY020678. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of
the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: rayyagari@ucsd.edu
Introduction
Retinal dystrophies (RD) are characterized by photoreceptor
degeneration and RPE atrophy causing loss of visual field and
acuities [1,2]. These degenerations are inherited in autosomal
dominant, autosomal recessive, X-linked, mitochondrial and
syndromic forms. More than 170 genes have been implicated in
causing RD (Retinal Information Network (RetNet), https://sph.
uth.tmc.edu/retnet/). Retinitis pigmentosa (RP) is a common form
of RD affecting 1 in 4000 individuals in the United States. The
clinical features of RP are delayed dark adaptation and progressive
loss of sensitivity, loss of peripheral vision at early stages
progressing to tunnel vision or in severe cases, to a total loss of
vision at later stages. About 60 genes involved in causing RP have
been reported (RetNet), of which 35 genes exhibit a recessive
mode of inheritance [3,4]. These 35 genes are estimated to
account for 30 to 50% of recessive RP cases [1]. Identifying
causative genes for RP has been challenging due to the significant
overlap in disease phenotypes and the lack of sufficient
information on phenotype-genotype associations.
Recent advances in exome capture and next generation
sequencing methodologies offer efficient strategies to identify the
genetic basis of inherited conditions in pedigrees that are not
suitable for linkage mapping [5,6]. These strategies can be used for
screening genes implicated in RD as well as for identifying novel
genes associated with RD and other related diseases [7,8]. In this
study we describe the identification of a novel splice site mutation
in the retinal binding protein-4 (RBP4) gene segregating with
recessive retinal degeneration in two affected siblings of a
consanguineous Caucasian pedigree and the potential implications
of the mutation.
RBP4 is a plasma protein that binds to retinol and facilitates
transport of retinol to peripheral tissues [9,10]. In humans, the
circulating RBP4-retinol complex is bound to transthyretin (TTR),
a homotetrameric thyroid hormone transport protein. Binding of
RBP4 to TTR increases its molecular mass thereby preventing its
removal by glomerular filtration [9], whereas, lack of TTR
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increases urinary excretion of RBP4 [9,11]. Retinol in peripheral
tissues is converted to retinaldehyde, a critical component of the
visual cycle [12]. Mice lacking retinol binding protein (RBP) were
found to be viable but exhibited impaired vision, demonstrating
that retinol binding protein plays an essential role in delivering
retinol to the eye [9]. Two teenage sisters identified to be
compound heterozygotes for mutations Ile41Asn (rs121918584)
and Gly75Asp (rs1218585) in the RBP4 gene with retinal
degeneration has been reported previously by Seelinger et al
[20]. One of these siblings had severe acne while the other had iris
coloboma. The siblings had no detectable serum retinol binding
protein and retinol levels were found to be one sixth of normal
levels. These results indicate that RBP4 is important in humans, as
RBP is in mice, in delivering retinol to the eye.
In the present study, exome capture and next generation
sequencing were carried out to identify the causative mutation in a
consanguineous pedigree with two affected members. The
progression of retinal pathology was studied in both patients over
a period of 17 years. The key feature of the affected siblings was
the presence of rod-cone degeneration. While one sibling had
ocular colobomas involving both the anterior and posterior
segment, the other sibling was without evidence of coloboma.
Identification of the mutation in this pedigree establishes the
association of RBP4 mutations with severe RD phenotype
involving ocular developmental abnormalities.
Subjects and Methods
Ethics statement
The studies presented in this manuscript have been approved by
the Institutional Review Board of the University of California San
Diego. All patient samples were collected with written informed
consent. All clinical investigations were conducted according to the
principles expressed in the Declaration of Helsinki.
Subjects
Information and blood samples were collected from eight
members across five generations of a Caucasian family (Figure 1).
Affected subjects IV-2 and IV-4 were examined longitudinally at a
seventeen year interval. Informed patient consent and local
institutional review board (IRB) approval were obtained for this
study which was conducted in accordance with the ethical
standards of the 1964 Declaration of Helsinki.
Ophthalmic evaluation
Ophthalmologic examination of the two affected siblings (IV-2
and IV-4) included best-corrected visual acuity, kinetic perimetry
with a Goldmann perimeter using standardized light targets V4e,
I4e and I2e, slit-lamp biomicroscopy, slit lamp photography,
fundus examination and photography. Absolute luminance
threshold to an 11u diameter achromatic central spot was
measured centrally and peripherally (10u and 20u) with a
Goldmann–Weekers adaptometer (Haag-Streit, Berne, Switzer-
land) following 45 min of dark adaptation
Full-field electroretinograms (ERGs) were recorded following
the standards of the International Society for Clinical Electro-
physiology of Vision [14] and using Burian–Allen bipolar contact
lens electrodes. An Ag/AgCl electrode was placed on the forehead
as the ground. Prior to ERG recording, pupils were dilated fully
with topical tropicamide (1%) and phenylephrine (2.5%), and the
patient was dark-adapted for 30 min. Scotopic rod-driven
responses were recorded first, followed by cone-driven photopic
single flash and 30 Hz flicker stimuli.
Exome caputure and sequencing
All exons in the genome, ‘‘exome,’’ of two affected and one
unaffected siblings (IV-2, IV-3 and IV-4) were captured using
NimbleGen SeqCap EX exome V1 probes (Roche NimbleGen,
Madison, WI) and sequenced using the Genome analyzer GAII
sequencer (Illumina, San Diego, CA) following manufacturers’
protocols.
Paired end (26100 bases) DNA sequence reads that passed the
quality control were mapped to the human reference genome
build hg19 using Bowtie (http://bowtie-bio.sourceforge.net/).
Variant calling and annotation were performed using SAMtools
(http://samtools.sourceforge.net/) and SeattleSeq (http://snp.gs.
washington.edu/SeattleSeqAnnotation/), respectively [15]. Only
variants mapping to a single site were further analyzed. Sequence
variants that were homozygous in the two affected siblings and
heterozygous or absent in the unaffected sibling were identified
and the allele frequency of each variant was obtained from dbSNP
version 132 reference database (or labeled as novel if not present).
Those variants present in genes implicated in retinal diseases were
selected for segregation analysis using standard polymerase chain
reaction (PCR) followed by dideoxy sequencing as described
earlier [16].
Segregation analysis of the RBP4 c.111+1G.A mutation
Primers that specifically amplify RBP4 exon 2 (Fwd: 59-GAT
TCC TGG GCA AGA TGA AG-39, Rev:59- AAG GAT GAC
AGC AGG GGT TT-39) were used for amplification and
sequencing. All available members of the pedigree and 100
ethnicity matched control individuals were screened for the RBP4
c.111+1G.A mutation.
Figure 1. Genetic analysis of a family with retinal degeneration.
A. Pedigree of the family with retinal degeneration. Family members
that were available for study were genotyped for the RBP4 c.111+1
G.A mutation. B. The reverse complement sequence of the
heterozygous subject IV-3 (G/A) and the homozygous subject IV-2 (A/
A) are shown. C. Protein encoding transcripts of RBP4 reported by
Ensembl (http://uswest.ensembl.org). Three protein coding transcripts
are reported by Ensembl. Transcripts ENST00000371464 and
ENST00000371467 encode the same protein (CCDS 31249).
ENST00000371469 does not have a CCDS identifier. The RBP4 c.111+1
mutation would affect all three of the predicted protein coding
transcripts.
doi:10.1371/journal.pone.0050205.g001
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Extraction and quantification of serum retinol by High-
Perormance Liquid chromatography (HPLC)
Serum retinol was assayed by reverse phase chromatography as
described previously [17]. Aliquots (50 mL) of serum from three
siblings in the pedigree (IV-2, IV-3 and IV-4) and a positive
control sample (consisting of 49.860.4 mg/dL retinol) were mixed
with 20 ng of retinyl acetate (Sigma Chemical Co., St. Louis, MO)
in 50 mL ethanol (1:1, vol:vol), and extracted twice with 0.5 mL
hexane. The retinol containing hexane extracts were pooled and
evaporated to dryness under a gentle stream of nitrogen. The
residue was dissolved in 100 mL of methanol and 20 mL of the
retinol sample was analyzed by HPLC (Thermo Scientific, San
Jose, CA), using a 15064.6 mm Microbondapack C8 (5 mm)
column (Millipore). Separation was achieved by using a mobile
phase consisting of methanol:water (95:5 V/V) at a flow rate of
1.0 mL/min. Retinol was monitored at 326 nm and quantified by
comparing the area under the curve with that of retinol (Sigma
Chemical Co., St. Louis, MO) analyzed along with the patient
samples. The recovery of retinyl acetate was .95%.
Immunoblotting analysis
Serum RBP4 and TTR protein levels were assessed by
immunoblotting as described previously using rabbit polyclonal
antibodies to human RBP4 protein (Cat#ab64194; Abcam,
Cambridge, MA) and human TTR developed by Raghu et al.
[18,19]. Briefly, the samples were separated by SDS 10%-PAGE
and electro-blotted onto nitrocellulose membrane. The mem-
branes were blocked in 5% non-fat dry milk and probed with
rabbit anti-human RBP4 or TTR antibody (1 mg, overnight at
4uC) followed by 1 h treatment with goat anti-rabbit IgG-
HRP(1:5000, Pierce). The blots were visualized using Super-
SignalH West Pico kit (Pierce Scientific, Rockford,IL).
Results
Pedigree
Both affected siblings had the same parents who were related as
second-cousins (Figure 1). Each parent harbored the RBP4
mutation in heterozygous fashion, as did their respective parent
(II:1 and III:8) from the family common relationship. Neither of
the parents nor their respective parents were examined, but all
reported normal vision and no ocular abnormalities. An unaffect-
ed female sibling (IV-3) reported having normal vision and no
ocular abnormalities.
Patient IV-2 Phenotype
The affected male (IV-2), was evaluated twice, at age 46 years
and again at age 63. He reported a lifelong history of impaired
night vision and loss of visual acuity from childhood and a history
of hypercholesterolemia. He had surgery for a patent ductus
arteriosus at age 46.
Ocular examination revealed anterior segment dysgenesis with
a small cornea (9 mm), inferiorly displaced pupil, and inferior
coloboma of the iris (Figure 2A). He also had evidence of
conjunctival and corneal limbal neovascularization, which ap-
peared to be secondary to exposure. The view of the posterior pole
was limited due to the presence of significant nuclear sclerotic
cataract. Fundus examination revealed inferior coloboma of the
retina and choroid (Figure 2B) in addition to the retinal
degeneration. At age 46, his vision was hand motion OD and
light perception OS. Seventeen years later at age 63 his vision was
further reduced to light perception in both eyes. Because of the
extent of retinal degeneration, his dark adaptation thresholds,
visual fields and ERGs could not be recorded at either visit.
Patient IV-4 Phenotype
The affected female (IV-4) was evaluated at age 38 years and
again at age 55. She reported peripheral vision abnormalities
beginning at age 10. Other medical problems include: hypercho-
lesterolemia, acne beginning at a young age and extending into
her 50 s, and spine surgery for osteoarthritis. Neither she nor her
affected brother had signs of xerophthalmia, keratomalacia, or
Bitot’s spots.
Her ocular exams revealed normal anterior segments without
evidence of coloboma or other abnormality (Figure 2C). Natural
lenses were present in both eyes. Her acuities at age 38 years were
20/20 OD and 20/60 OS. Seventeen years later at age 55, her
acuities had diminished to 20/32 OD and only hand motion OS.
Fundus evaluation revealed evidence of retinal degeneration in
both eyes with peripheral retinal atrophy, intraretinal ‘‘bone
spicule’’ pigmentation and attenuated retinal arterioles. An island
relatively intact retina remained in the central few degrees of the
macula surrounding the fovea (Figure 2D).
Testing demonstrated severely constricted visual fields OU to
less than 5 degrees centrally with a temporal island for both eyes
with larger target sizes (Figure 3C and 3D). Evidence of
progression in retinal disease is evident across the 17 year interval,
as her fields at age 38 were larger centrally and temporally OU
(Figures 3A and 3B). By age 55 her dark adapted absolute
thresholds centrally were elevated 3–4 log units above rod normal
thresholds and were consistent with perception by cones. There
were no detectable thresholds at 10 degree and 20 degree
eccentricity, consistent with total loss of field sensitivity at these
locations on Goldmann perimetry. This was worse than 17 years
earlier, as her central threshold then was 2 log units elevated above
normal and peripheral sensitivity was detectable at 10 degrees and
20 degrees from fixation thresholds at 3–4 log units elevated over
normal rod threshold.
Figure 2. Ocular examination of affected patients IV- 2 at age
63 and IV-4 at age 55. Patient IV-2 exhibited anterior segment
dysgenesis with a small cornea, inferiorly displaced pupil, and inferior
coloboma of the iris with corneal limbal neovascularization (panel A).
The fundus shows an inferior coloboma of the retina and choroid and
severe chorioretinal atrophy (panel B). Patient IV-4 has normal anterior
segments coloboma or other abnormalities (panel C). The fundus in
both eyes was similar with widespread retinal degeneration comprising
extensive peripheral retinal atrophy, ‘‘bone spicule’’ pigmentation
throughout except for the central-most macula, and markedly
attenuated retinal arterioles (panel D).
doi:10.1371/journal.pone.0050205.g002
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ERG scotopic rod-driven responses were not detectable at
either visit (data not shown). Cone photopic single flash responses
were approximately 80% reduced at age 38 years, and these
residual cone responses were further reduced to the level of noise
17 years later (Figure 4A). 30 Hz flicker ERG testing demonstrat-
ed a similar decline in this cone elicited response (Figure 4B).
Exome Analysis
Exome capture and next generation sequencing of patients IV-2
and IV-4 and their unaffected sibling (IV-3) identified ,8,800–
12,000 known single nucleotide variants (SNV) and 1000–1700
novel SNVs in the three subjects. The recessive pattern of
inheritance of retinal abnormalities and consanguinity in the
pedigree suggested the potential involvement of a homozygous
mutation in causing RD in the study family. Analysis of the
sequence variants detected in the exomes of all three siblings
identified 49 variants that were homozygous in the two affected
siblings and simple heterozygous or wild type in the unaffected
sibling in 40 unique genes as possible candidates for disease (Table
S1). Of these, only RBP4 was a gene that had been previously
reported to be associated with retinal degeneration [20].
Mutation analysis by dideoxy sequencing
Sequencing analysis of the RPB4 gene in the DNA of all
available members of the pedigree revealed the presence of
c.111+1G.A change in the homozygous state in intron 2 in both
affected members while the unaffected sibling and both parents
have this change in the heterozygous state (Figure 1). Analysis of
additional members of the pedigree confirmed segregation of this
sequence change with the retinal degeneration phenotype.
Analysis of 100 ethnicity matched normal controls with no known
history of retinal degeneration did not reveal this change
Figure 3. Goldman Visual Field (GVF) of the patient IV-4 at age 38 and at age 55. GVF demonstrated progressive loss from retinal disease.
At age 38, both eyes showed a central ‘‘tunnel’’ vision of 15 degrees and large peripheral temporal islands OU (panel A and B), but by age 55, these
had constricted to less than 5 degrees, with a small temporal islands for both eyes (panel C and D).
doi:10.1371/journal.pone.0050205.g003
Figure 4. Electroretinogram responses from patient IV-4 with
photopic single flash and 30 Hz flicker response stimuli. Both
panels show responses at younger age 38 years on top and at 55 years
on bottom. The single flash cone responses at age 38 was reduced
approximately 80% from normal and was no longer detectable 17 years
later (Panel A). The cone flicker response was similarly reduced at age
38 and further diminished by age 55 (Panel B).
doi:10.1371/journal.pone.0050205.g004
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indicating that this variant is not likely to be a common variant in
this population. The c.111+1G.A change is predicted to disrupt
the splice site resulting in alteration of the RBP4 protein sequence.
In-silico analysis using the NetGene2 software or GeneSplicer
software did not identify additional splice sites in the mutant RBP4
sequence.
Serum RBP4 protein expression
Western blot analysis was performed to determine the effect of
the RBP4 c.111+1G.A mutation on RBP4 serum protein levels
(Figure 5, top panel). Antibodies to the RBP4 detected the
presence of a single immunoreactive band corresponding to the
RBP4 protein (,23 kDa) in the control serum and in the serum of
the unaffected sibling (IV-3 in Figure 1). The immunoreactive
band corresponding to RBP4 protein was not detected in the
serum of the affected patients (Figure 5, top panel, lanes IV-2, IV-
4). If the mutation caused the in frame inclusion of 37 amino acids
predicted to be encoded by intron 2, the resulting mutant protein
would be 26.6 kDa. We observe a faint band of ,26 kDa in both
affected siblings and the unaffected sibling which may represent
low levels of the mutant protein (Figure 5: Asterisk). Absence of the
wild type RBP4 protein band in IV-2 and IV-4 indicates that the
homozygous splice site change affects splicing of the RBP4 gene
and stability of the mutant RNA or protein.
Serum Transtheyretin (TTR) protein expression
Since absence of transthyretin would also contribute to loss of
RBP4 from serum, TTR levels were examined in patients with
and without the RBP4 c.111+1G.A mutation by western blot
analysis. Presence of immunoreactive bands corresponding to
TTR 15 kDa monomer and 30 kDa dimer protein were detected
in the control, unaffected sibling, and in both patients (Figure 5b,
lanes 1–5) indicating the presence of TTR in patients homozygous
for the RBP4 c.111+1 G.A mutation.
Serum retinol levels
Since absence of RBP4 is expected to cause a reduction in
serum retinol levels, we examined the effect of the RBP4
c.111+1G.A mutation on serum retinol levels (Table 1). Retinol
was undetectable in the RD affected subjects, while the levels were
49.860.4 mg/dL in the control and 3060.7 mg/dL in the
unaffected sister.
Discussion
Exome sequencing of three members of a consanguineous
pedigree identified a novel homozygous RBP4 mutation in two
members with retinal degeneration. Analysis of RBP4, TTR and
levels of retinol in serum further established the effect of
c.111+1G.A mutation and its association with the retinal
degeneration phenotype observed in this pedigree.
The novel mutation in the RBP4 gene is predicted to disrupt a
donor splice site and would affect the mature proteins translated
from the three primary protein coding transcripts
(ENST00000371464, ENST00000371469, ENST00000371467)
(Figure 1c). The RBP4 protein (CCDS 3149) has 201 amino acids
with a signal peptide (1–16 aa), retinol binding and lipocalin
domains [21]. The predicted mutant RPB4 protein would retain
an additional 37 N-terminal amino acids after the signal peptide
caused by the in frame inclusion of intron 2, resulting in a total of
238 amino acids. In silico analysis did not predict the presence of a
cryptic splice site that would result in a frame-shifted and
truncated protein. A 238 aa mutant RPB4 protein, if stable,
would retain both lipocalin and retinol binding domain sequences
and the signal peptide. Western blot analysis of the serum of
patients did not reveal the presence of immunopositive band
corresponding to the wild type protein, but detected a faint band
in the region of a predicted RBP4 mutant protein. These results
demonstrate that the RBP4 mutation causes either RNA or protein
instability. RBP4 is the carrier of retinol in human plasma and is
involved in transport of retinol from liver to peripheral tissue
including the retina [10]. Lack of RBP4 is expected to affect the
levels of serum retinol [9,13]. Consistent with this, the levels of
serum retinol were undetectable in both patients with the RBP4
mutation as compared to their unaffected sister and a normal
control. Increased urinary excretion of RBP-retinol complex also
Figure 5. Serum RBP4 and transthyretin (TTR) levels in affected
and unaffected family members. Serum RBP4 and TTR levels were
examined by western blot analysis as described in Methods. A) The
patients, IV-2 and IV-4 had undetectable levels of wild type RBP4 in
contrast to their unaffected sibling and the control. A faint band was
observed in the region of predicted mutant RBP4 in both patients and
their unaffected sibling (Asterisk). B) TTR levels (TTR monomer (15 kDa)
and dimer (30 kDa) were indistinguishable between affected and
unaffected subjects.
doi:10.1371/journal.pone.0050205.g005
Table 1. Levels of serum retinol in siblings with the RBP4
c.111+1 G.A change.
Sample (c.111+1 G.A) Retinol (mg/dL)
Control (Wild type) 49.860.4
IV-2 (Homozygous) undetectable
IV-3 (Heterozygous) 30.060.7
IV-4 (Homozygous) undetectable
doi:10.1371/journal.pone.0050205.t001
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occurs with absence of TTR [11] or by blocking the RBP-TTR
interaction [22], leading to reduced serum retinol levels
[10,11,22]. However, the TTR levels of patients with RBP4
c.111+1 G.A mutation and unaffected sibling remained similar,
implying that reduced RBP4 levels in both affected siblings is not
due to a lack of TTR. Presence of TTR, absence of RBP4 and
significantly lowered levels of retinol in both patients with the
c.111+1G.A mutation indicate that this mutation causes the loss
of functional RBP4 protein and, as a consequence, serum retinol
deficiency.
Lack of normal levels of retinol impairs the visual cycle resulting
in night blindness at early stages and prolonged deficiency may
lead to retinal degeneration [12,23]. Non-ocular symptoms of
retinol deficiency may include dry skin, increased susceptibility to
infection and acne [24,25]. Furthermore it is well established that
vitamin A plays a key role in embryonic development including
optic fissure closure [26]. Patient IV-2 had prominent develop-
mental abnormalities including patent ductus arteriosus, choroidal
and iris colobomas. However, his sister IV-4 did not present signs
of developmental abnormalities, but she had acne even in the 5th
decade. These indicate variation in the severity of the retinal
degeneration phenotype, developmental abnormalities and non-
ocular abnormalities in these two siblings with the RBP4
c.111+1G.A mutation. This variation could be due to either
genetic modifiers or nutritional factors such as maternal or dietary
vitamin A levels during fetal development and adulthood
respectively. Lack of other classical symptoms of vitamin A
deficiency including xerophthalmia, keratomalacia, or Bitot’s spots
in these patients suggest that some dietary vitamin A is being
delivered to organs independent of RBP4, but RBP4 is required to
deliver sufficient levels of vitamin A to prevent retinal degener-
ation. Therefore, measuring serum RBP4, TTR and retinol levels
may be a useful way to identify RD patients with mutations in
genes that affect vitamin A levels.
Ocular colobomas associated with other abnormalities have
been reported [27]. Although the retinal pathology associated with
RBP4 mutations is indistinguishable from the recessive RD
phenotype due to mutations in other genes, the additional
presence of acne or developmental abnormalities is unique to
patients with RPB4 associated RD [3].
The retinal degeneration associated with the RBP4 homozygous
splice site mutation in our two siblings progressed significantly over
a 17-year interval between our examinations in middle age. These
patients reported that their vision loss was substantially less severe
during their teenage years, but that it became quite severe in their
4th and 5th decade such that one had essentially no remaining
functional vision by age 45 years. The only other individuals
reported with RBP4 associated RD were two siblings studied by
Seelinger et al, who were 13 and 17 years old at the time of the
study and had less profound phenotypic changes suggesting the
progressive nature of retinal disease caused by RBP4 mutations
[20]. Our patients (IV-2 and IV-4) reported using high dose
vitamin A supplementation during the 17 years between exam-
inations. During this time their vision loss progressed significantly
but supplementation may have contributed to the lack of
development of other symptoms of vitamin A deficiency including
Bitot spots.
The broad genotypic and phenotypic heterogeneity observed in
retinal dystrophies with the involvement of well over 150 known
genes underlying cases of recessive RD clearly indicate the need
for employing an efficient, cost-effective genome wide mutation
screening protocol. Currently, the availability of tools to sequence
the exome, identify variants and determine their effect on the
protein makes exome analysis the primary choice to identify
causative mutations. This methodology is suitable to screen for
mutations in known and novel genes even in smaller pedigrees
such as the one presented in this study.
In summary, exome sequencing and analysis of variants in three
siblings from a consanguineous pedigree revealed that a novel
homozygous RBP4 splice site mutation is associated with RD. The
RD phenotype associated with the RBP4 mutation is progressive
and results in severe vision loss by middle age. RBP4 RD was also
associated with the presence of developmental abnormalities and
severe acne in these patients and may be a hallmark of RBP4
associated RD. Analysis of serum vitamin A levels and serum
RPB4 may serve as a cost effective initial screening method in
determining the potential involvement of RBP4 in patients with
retinal degeneration, specifically those with ocular colobomas.
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